ArticleNature medicine2018
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 172 papers.
0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
172 citing papers in PubMed, 271 citations in OpenAlex.
- Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.Cancer discovery · 2021Trial
- BGC1201: A potent allosteric SHP2 inhibitor with broad antitumor activity in lung, pancreatic, and esophageal cancer xenografts.Pharmaceutical science advances · 2026Article
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- SHP2 as a pivotal modulator of the tumor microenvironment in gastrointestinal cancers: from mechanisms to targeted therapies.Journal of translational medicine · 2026Review
- Posttranslational modifications remodel proteome-wide ligandability.Nature chemical biology · 2026Article
- Risk assessment of secondary primary malignancies: results from two large prospective European cohorts.NPJ precision oncology · 2026Article
- Article
- Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.Targeted oncology · 2026Article
- Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.Molecular cancer research : MCR · 2026Article
- The Interplay Between Esophageal Adenocarcinoma and Its Tumor Microenvironment: Toward Innovative Therapies.Cells · 2025Review
- The CTLH ubiquitin ligase substrates ZMYND19 and MKLN1 negatively regulate mTORC1 at the lysosomal membrane.Nature communications · 2025Article
- Review
- Non-coding RNAs-mediated regulation of the MAPK pathway in gastric cancer: translational perspectives.Discover oncology · 2025Review
- KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy.Journal of translational medicine · 2025Article
- Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.Cancer biology & medicine · 2025Review
- Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.Molecular cancer therapeutics · 2025Article
- SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASProceedings of the National Academy of Sciences of the United States of America · 2025Article
- PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers.The Journal of experimental medicine · 2025Article
- Discovery of Small Molecules that Bind to Son of Sevenless 2 (SOS2).Journal of medicinal chemistry · 2025Article
112 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
38 authors at 13 institutions in 4 countries.
Gabrielle S WongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jin ZhouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jie Bin LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Zhong WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Xinsen XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tianxia LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David XuDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA.
Steven E SchumacherCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jens PuschhofDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
James McFarlandDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Charles ZouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Austin DulakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Les HendersonDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA.
Peng XuDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA.
Emily O'DayDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA.
Rachel RendakDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA.
Wei-Li LiaoOncoPlex Diagnostics/NantOmics, Rockville, MD, USA.
Fabiola CecchiOncoPlex Diagnostics/NantOmics, Rockville, MD, USA.
Todd HembroughOncoPlex Diagnostics/NantOmics, Rockville, MD, USA.
Sarit SchwartzOncoPlex Diagnostics/NantOmics, Rockville, MD, USA.
Christopher SzetoOncoPlex Diagnostics/NantOmics, Rockville, MD, USA.
Anil K RustgiDivision of Gastroenterology, Departments of Medicine and Genetics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kwok-Kin WongDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
J Alan DiehlDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.ORCID http://orcid.org/0000-0001-9854-5049
Karin JensenSanofi Oncology, Cambridge, MA, USA.
Francesco GrazianoDepartment of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.
Annamaria RuzzoDepartment of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.
Shaunt FereshetianCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Philipp MertinsCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Steven A CarrCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7203-4299
Rameen BeroukhimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kenichi NakamuraDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Masayuki WatanabeDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Hideo BabaDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Yu ImamuraDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Daniel CatenacciDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA. dcatenac@bsd.uchicago.edu.
Adam J BassDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. adam_bass@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBroad Institute · USUniversity of Chicago Medical Center · USOncoPlex Diagnostics (United States) · USKumamoto University · JPThe Cancer Institute Hospital · JPUniversity of Urbino · ITCambridge Scientific (United States) · USHarvard University · USKyushu University · JPMedical University of South Carolina · USUniversity of Illinois Urbana-Champaign · USUniversity of Pennsylvania · US
Funding
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI CHIEN-MIN KAO · 1985 to 2026
$122.1MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2MTransformed Esophageal Epithelial Cells and the Tumor MicroenvironmentP01CA098101 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RUSTGI, ANIL K · 2003 to 2023
$31.7MPANGEA: Personalized Antibodies for GastroEsophageal Adenocarcinoma Pilot TrialK23CA178203 · NCI · UNIVERSITY OF CHICAGO · PI CATENACCI, DANIEL · 2014 to 2016
$507kNCI NIH HHS K23 CA178203NCI NIH HHS P01 CA098101NCI NIH HHS P30 CA014599NCI NIH HHS P50 CA127003
Abstract
The role of KRAS, when activated through canonical mutations, has been well established in cancer
Indexed as
Gene AmplificationAnimalsCell Line, TumorDisease Models, AnimalEsophageal NeoplasmsHumansMiceMitogen-Activated Protein Kinase KinasesPiperidinesProtein Kinase InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)PyridonesPyrimidinesPyrimidinonesStomach NeoplasmsKRAS protein, humanMitogen-Activated Protein Kinase KinasesPiperidinesProtein Kinase InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)PyridonesPyrimidinesPyrimidinonesSHP099trametinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.